Strategic Advisors LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.0% during the 4th quarter, HoldingsChannel reports. The fund owned 11,654 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the period. Strategic Advisors LLC’s holdings in Gilead Sciences were worth $835,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in GILD. Welch Investments LLC bought a new position in shares of Gilead Sciences during the 3rd quarter valued at $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences during the 3rd quarter valued at $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences during the 3rd quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences during the 2nd quarter valued at $147,000. Finally, Hanson & Doremus Investment Management lifted its holdings in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares during the period. 76.47% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have recently weighed in on GILD. Mizuho reissued a “buy” rating and set a $95.00 price target (up from $83.00) on shares of Gilead Sciences in a report on Monday, February 12th. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target on the stock in a report on Monday, February 12th. BMO Capital Markets increased their price target on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a report on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, February 7th. Finally, Citigroup reissued a “buy” rating and set a $105.00 price target (up from $103.00) on shares of Gilead Sciences in a report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $87.04.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter in the prior year, the business posted $2.70 EPS. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year. equities analysts expect that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is presently 59.77%.
In other news, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares in the company, valued at $254,587,766.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gayle E. Wilson sold 60,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $77.92, for a total value of $4,675,200.00. Following the transaction, the director now owns 182,258 shares of the company’s stock, valued at approximately $14,201,543.36. The disclosure for this sale can be found here. Insiders sold a total of 418,333 shares of company stock valued at $32,742,108 in the last quarter. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.